When B cells rebuff bispecifics

Adam J Olszewski,Adam J. Olszewski
DOI: https://doi.org/10.1182/blood.2023023312
IF: 20.3
2024-03-02
Blood
Abstract:Bispecific antibodies directed against CD20 and CD3 have recently captivated the attention of lymphoma oncologists, challenging chimeric antigen receptor (CAR) T-cell therapy in terms of enthusiasm, yet also raising questions about predictive biomarkers and underlying mechanisms of resistance. In this issue of Blood , Schuster et al show that antigen escape, predominantly related to acquired mutations in MS4A1 (the gene encoding CD20), is a major cause of B-cell lymphoma progression after treatment with the CD20xCD3 bispecific antibody mosunetuzumab. 1 Using tumor samples from the phase 1/2 GO29781 trial, which enrolled patients with a variety of relapsed/refractory B-cell lymphomas, 2 the authors found loss of CD20 expression in 34% of biopsies collected at the time of disease progression after mosunetuzumab treatment.
hematology
What problem does this paper attempt to address?